NCT05169710 / 2021-002126-24: A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder. |
|
|
| Terminated | 3 | 83 | Europe, Canada, Japan, US | SEP-4199 CR 200 mg, SEP-4199 CR 400 mg, Placebo | Sumitomo Pharma America, Inc., Sunovion Pharmaceuticals Inc. | Depressive Episodes, Bipolar I Depression | 10/23 | 10/23 | | |
ENLIGHTEN, NCT05113771: A Biomarker-Guided, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With Treatment-Resistant Depression |
|
|
| Completed | 2 | 197 | Canada, US | Liafensine, Placebo | Denovo Biopharma LLC | Treatment Resistant Depression | 02/24 | 03/24 | | |